Corvus Pharmaceu Stock Price, News & Analysis

Corvus Pharmaceuticals (NASDAQ: CRVS) reported positive Phase 1 clinical trial data for soquelitinib in treating moderate to severe atopic dermatitis. Cohort 3 (200mg twice daily) showed superior results compared to cohorts 1-2, with a 64.8% mean EASI score reduction vs 54.6% for cohorts 1-2 and 34.4% for placebo at day 28. The drug demonstrated statistically significant improvement (p=0.036) and earlier response onset, with itch reduction observed as early as day 8. Safety profile was favorable with no dose-limiting toxicities. Notably, 50% of evaluable Cohort 3 patients achieved clinically meaningful itch reduction. The company has initiated an extension study with an 8-week treatment period at the Cohort 3 dose level to explore longer-duration benefits.

Corvus Pharmaceuticals (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, has announced its participation in the 2025 Jefferies Global Healthcare Conference in New York. The company's leadership team will deliver a corporate overview presentation on Thursday, June 5, from 9:20-9:50 am ET and conduct one-on-one meetings with investors. A webcast of the presentation will be available live and accessible for 90 days after the event through the investor relations section of Corvus's website.

<p><b>Corvus Pharmaceuticals (CRVS)</b> reported Q1 2025 financial results and provided key business updates. The company's lead drug <b>soquelitinib</b> showed favorable safety and efficacy in Phase 1 trials for atopic dermatitis, with cohort 3 (200mg twice daily) demonstrating earlier and deeper responses compared to lower doses. The company received <b>$31.3 million from early warrant exercises</b> by stockholders at $3.50 per share.</p><p>Financial highlights include cash position of <b>$44.2 million</b> as of March 31, 2025, with operations funded into Q4 2026. Q1 2025 showed <b>net income of $15.2 million</b>, including a $25.1 million warrant liability gain. R&D expenses increased to <b>$7.5 million</b>, up from $4.1 million in Q1 2024.</p>

Corvus Pharmaceuticals (NASDAQ: CRVS) reported positive interim data from its Phase 1 clinical trial of soquelitinib for moderate to severe atopic dermatitis. The trial showed favorable safety and efficacy profiles, with Cohort 3 (200mg twice daily) demonstrating earlier and deeper responses compared to Cohorts 1-2. Key findings include: - Cohort 3 achieved 71.1% reduction in mean EASI score vs 42.1% for placebo - Combined Cohorts 1-2 showed 54.6% reduction vs 30.6% for placebo - Treatment was well-tolerated with no dose-limiting toxicities - Positive biomarker results showing reduction in inflammatory cytokines Based on these results, Corvus has amended the trial protocol to evaluate an additional 24 patients at 200mg twice daily for an extended 8-week treatment period. The company plans to initiate a Phase 2 trial by year-end.

Corvus Pharmaceuticals (NASDAQ: CRVS) has announced upcoming presentations of new interim data from their Phase 1 clinical trial of soquelitinib for atopic dermatitis treatment. The data, from Cohorts 1-3 of the randomized, double-blind, placebo-controlled trial, will be presented at the Society for Investigative Dermatology (SID) 2025 Annual Meeting in San Diego.

Dr. Albert S. Chiou from Stanford University Medical Center will present the findings titled 'Selective Soquelitinib, a selective ITK inhibitor demonstrates activity in atopic dermatitis phase 1 clinical trial by a novel mechanism of action' through both an oral presentation and poster session on May 8-10, 2025.

The company will discuss these results during their first quarter 2025 business update conference call scheduled for May 8, 2025.

Corvus Pharmaceuticals (NASDAQ: CRVS) has appointed Richard van den Broek to its Board of Directors. Van den Broek, currently managing partner at HSMR Advisors, brings over 30 years of experience in the life sciences industry as an investor, biotechnology equity research analyst, and board member.

Van den Broek currently serves on the boards of Pulse Biosciences and Cogstate , and previously served on Pharmacyclics' board until its acquisition by AbbVie in 2015. He holds an A.B. degree from Harvard University and is a Chartered Financial Analyst.

The appointment aims to leverage his expertise in ITK inhibition, which Corvus is developing to modulate and control parallel signaling pathways in the immune system for treating immune diseases and cancers.

Corvus Pharmaceuticals (CRVS) has reported its Q4 and full year 2024 financial results, highlighting progress in its clinical programs. The company's lead drug soquelitinib showed promising interim results in atopic dermatitis trials, with 26% of patients achieving IGA 0/1 and 37% achieving EASI 75 in the first two cohorts, compared to zero in the placebo group.

The company is advancing multiple clinical trials, including a Phase 3 registration trial for peripheral T cell lymphoma (PTCL) and a new Phase 2 trial for autoimmune lymphoproliferative syndrome (ALPS). Financial results show cash position of $52.0 million as of December 31, 2024, up from $27.1 million in 2023. R&D expenses increased to $19.4 million for full year 2024, compared to $16.5 million in 2023. The company reported a Q4 net loss of $12.1 million.

Through a registered direct offering and warrant exercises, Corvus raised approximately $48.9 million in 2024. The company expects current cash to fund operations into Q1 2026.

Corvus Pharmaceuticals (NASDAQ: CRVS) has presented additional data from its Phase 1/1b clinical trial of soquelitinib for T cell lymphoma (TCL) treatment at the 16th Annual T-Cell Lymphoma Forum. The trial showed promising results with:

• 39% objective response rate (9 out of 23 evaluable patients)
• 26% complete response rate (6 patients)
• 17.2 months median duration of response
• 6.2 months median progression-free survival
• 30% progression-free survival rate at 18 months

The company is currently conducting a registrational Phase 3 trial enrolling 150 patients with relapsed Peripheral T cell lymphoma, comparing soquelitinib to belinostat or pralatrexate. Soquelitinib has received FDA Orphan Drug Designation for T cell lymphoma and Fast Track designation for relapsed/refractory PTCL treatment.

Corvus Pharmaceuticals (NASDAQ: CRVS) has announced its participation in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference. The clinical-stage biopharmaceutical company's leadership team will engage in one-on-one meetings with investors and participate in a fireside chat presentation scheduled for March 27, 2025, at 12:00 pm ET.

The virtual presentation will be accessible through a webcast that will remain available for 90 days after the event via the company's investor relations website section.